Drug intelligence / Profile preview

ART8

Development stage: Preclinical
Lead developer: Arnatar Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

ART8 is a small interfering RNA (siRNA) therapeutic candidate being developed by Arnatar Therapeutics for the treatment of inflammatory diseases. It is currently in the discovery stage of development. ART8 utilizes Arnatar's proprietary DARGER™ platform, which is designed for the delivery and optimization of RNA-based therapies. The specific biological target of ART8 has not been disclosed by the company, but the mechanism involves the downregulation of a target gene implicated in inflammatory processes.

Beyond the preview

Go deeper on ART8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART8.

Explore the full profile